ChiCTR2600122378 版本V1.0 版本创建时间2026/04/13 15:02:14 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600122378 

最近更新日期:

Date of Last Refreshed on:

2026-04-13 15:01:57 

注册时间:

Date of Registration:

2026-04-13 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

重复经颅磁刺激改善胸腔镜肺部手术患者术后恢复质量的疗效:一项随机对照试验

Public title:

Efficacy of Repetitive Transcranial Magnetic Stimulation on Postoperative Recovery Quality in Patients Undergoing Video-Assisted Thoracic Surgery: A Randomized Controlled Trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

重复经颅磁刺激改善胸腔镜肺部手术患者术后恢复质量的疗效:一项随机对照试验

Scientific title:

Efficacy of Repetitive Transcranial Magnetic Stimulation on Postoperative Recovery Quality in Patients Undergoing Video-Assisted Thoracic Surgery: A Randomized Controlled Trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

毛庆祥 

研究负责人:

毛庆祥 

Applicant:

Qingxiang Mao 

Study leader:

Qingxiang Mao 

申请注册联系人电话:

Applicant telephone:

+86 13594054231

研究负责人电话:

Study leader's telephone:

+86 13594054231

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

qxmao@tmmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

maomaosmmu@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区大坪长江支路10号

研究负责人通讯地址:

重庆市渝中区长江支路10号陆军特色医学中心

Applicant address:

No. 10 Changjiang Branch Road, Yuzhong District, Chongqing

Study leader's address:

No. 10 Changjiang Branch Road, Yuzhong District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国人民解放军陆军特色医学中心

Applicant's institution:

Army Medical Center of PLA

研究负责人所在单位:

中国人民解放军陆军特色医学中心

Affiliation of the Leader:

Army Medical Center of PLA

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

医研伦审(2025)第418号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军陆军特色医学中心临床科研伦理委员会

Name of the ethic committee:

Ethics Committee of Army Medical Center of PLA

伦理委员会批准日期:

Date of approved by ethic committee:

2026-02-09 00:00:00

伦理委员会联系人:

王晶晶

Contact Name of the ethic committee:

Wang Jingjing

伦理委员会联系地址:

重庆市渝中区长江支路10号陆军特色医学中心

Contact Address of the ethic committee:

Army Medical Center of PLA, No. 10 Changjiang Branch Road, Yuzhong District, Chongqing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 23 68757140

伦理委员会联系人邮箱:

Contact email of the ethic committee:

wii1017@163.com

研究实施负责(组长)单位:

中国人民解放军陆军特色医学中心

Primary sponsor:

Army Medical Center of PLA

研究实施负责(组长)单位地址:

重庆市渝中区长江支路10号

Primary sponsor's address:

No. 10 Changjiang Branch Road, Yuzhong District, Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆市

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

中国人民解放军陆军特色医学中心

具体地址:

重庆市渝中区长江支路10号

Institution
hospital:

Army Medical Center of PLA

Address:

No. 10 Changjiang Branch Road, Yuzhong District, Chongqing

经费或物资来源:

重庆市自然科学基金面上项目

Source(s) of funding:

Chongqing Natural Science Foundation (General Program)

Target disease:

postoperative recovery quality

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评估围术期应用重复经颅磁刺激对胸腔镜肺部患者术后早期恢复质量的综合影响。  

Objectives of Study:

To evaluate the comprehensive impact of perioperative repetitive transcranial magnetic stimulation on early postoperative recovery quality in patients undergoing video-assisted thoracic surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄:大于18周岁; 2. ASA分级:I-III 级 ; 3. 手术类型:拟择期行胸腔镜肺部手术的患者 ; 4. 知情同意:患者自愿参与并签署书面知情同意书。

Inclusion criteria

1. Age: greater than 18 years old; 2. ASA classification: I-III; 3. Type of surgery: patients scheduled for elective thoracoscopic lung surgery; 4. Informed consent: patients voluntarily participate and sign written informed consent.

排除标准:

1.存在颅内金属植入物、心脏起搏器或植入式心律转复除颤器(ICD)、耳蜗植入物;有癫痫个人史或家族史; 2.有神经系统与精神疾病史; 3.存在严重的听力、视力、语言或认知功能障碍,经研究者判断无法配合完成TMS治疗及术后随访评估; 4.有明确的药物或酒精滥用史; 5.术前已有慢性疼痛史,并长期规律使用阿片类镇痛药物; 6.合并严重的心、肝、肾功能障碍。

Exclusion criteria:

1. Presence of intracranial metal implants, cardiac pacemaker, implantable cardioverter-defibrillator (ICD), or cochlear implant; Personal or family history of epilepsy; 2. History of neurological or psychiatric disorders; 3. Severe hearing, visual, speech, or cognitive impairment that, in the investigator's judgment, precludes cooperation with TMS treatment and postoperative follow-up assessments; 4. Clear history of drug or alcohol abuse; 5. Pre-existing history of chronic pain with long-term regular use of opioid analgesics; 6. Concurrent severe cardiac, hepatic, or renal dysfunction.

研究实施时间:

Study execute time:

From 2026-02-01 00:00:00 To 2027-02-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-13 00:00:00 To 2027-02-01 00:00:00  

干预措施:

Interventions:

组别:

对照组

样本量:

72

Group:

Control group

Sample size:

干预措施:

假刺激

干预措施代码:

Intervention:

Sham stimulation

Intervention code:

组别:

试验组

样本量:

72

Group:

Test group

Sample size:

干预措施:

重复经颅磁刺激

干预措施代码:

Intervention:

Repetitive transcranial magnetic stimulation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆市 

市(区县):

 

Country:

China 

Province:

Chongqing 

City:

 

单位(医院):

中国人民解放军陆军特色医学中心 

单位级别:

三级甲等 

Institution
hospital:

Army Medical Center of PLA

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后肺部并发症

指标类型:

次要指标

Outcome:

Postoperative pulmonary complications

Type:

Secondary indicator

测量时间点:

术后72h内

测量方法:

每日病例审查,术前及术后胸部影像学检查与临床实验室检查。

Measure time point of outcome:

within 72 hours postoperatively

Measure method:

Daily case review, along with pre- and postoperative chest imaging and clinical laboratory tests.

指标中文名:

术后睡眠质量

指标类型:

次要指标

Outcome:

Postoperative sleep quality

Type:

Secondary indicator

测量时间点:

术后24h,48h

测量方法:

RCSQ理查兹-坎贝尔睡眠量表

Measure time point of outcome:

Postoperative 24h, 48h

Measure method:

Richards-Campbell Sleep Questionnaire

指标中文名:

术后24h恢复质量

指标类型:

主要指标

Outcome:

Postoperative 24-hour Recovery Quality

Type:

Primary indicator

测量时间点:

术后24h

测量方法:

QoR-15量表

Measure time point of outcome:

Postoperative 24h

Measure method:

QoR-15

指标中文名:

术后48h恢复质量

指标类型:

次要指标

Outcome:

Postoperative 48-hour Recovery Quality

Type:

Secondary indicator

测量时间点:

术后24h

测量方法:

QoR-15量表

Measure time point of outcome:

Postoperative 48h

Measure method:

QoR-15

指标中文名:

术后疼痛

指标类型:

次要指标

Outcome:

postoperative pain

Type:

Secondary indicator

测量时间点:

术后24h,48h

测量方法:

NRS数字评分法

Measure time point of outcome:

Postoperative 24h, 48h

Measure method:

Numeric Rating Scale

指标中文名:

术后焦虑与抑郁状态

指标类型:

次要指标

Outcome:

Postoperative anxiety and depressive symptoms

Type:

Secondary indicator

测量时间点:

术后24h,48h

测量方法:

HADS医院焦虑抑郁量表

Measure time point of outcome:

Postoperative 24h, 48h

Measure method:

Hospital Anxiety and Depression Scale (HADS)

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机化采用区组随机法(区组大小为4或6的可变区组),由未参与本研究的协调者使用 R 4.5.0 软件生成1:1比例的随机序列,未进行分层。

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomization was conducted using a block randomization method (with variable block sizes of 4 or 6). A non-participating coordinator generated a 1:1 random sequence using R 4.5.0 software without stratification.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

双盲

Blinding:

Double blind

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

本研究产生的数据将由申办方/研究者按照相关法律法规及本机构数据管理制度统一保存和管理。所有研究数据在统计分析前均进行去标识化处理,不含受试者直接身份标识信息。 预计共享时间: 研究主要结果发表后6个月内,或研究结束后3年内(以先达到者为准)。 共享方式: 研究数据暂不对社会公开发布。如有合格研究者提出合理、合法的学术研究需求,在签署数据使用/保密协议并经申办方及伦理委员会/数据管理部门审批后,可通过受控访问机制提供必要的数据访问或共享。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The data generated from this study will be uniformly stored and managed by the sponsor/investigator in accordance with relevant laws, regulations, and the data management policies of the institution. All study data will be de-identified prior to statistical analysis, without containing any direct personal identifiers of the participants.Expected Timeline for Sharing: Within 6 months after the publication of the primary study results, or within 3 years after the completion of the study, whichever comes first.Sharing Method: The study data will not be publicly available. Qualified researchers with reasonable and legitimate academic research needs may, after signing a data use/confidentiality agreement and obtaining approval from the sponsor and the Ethics Committee/Data Management Authority, be granted necessary data access or sharing through a controlled access mechanism.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

(1)建立组织管理体系和制定规范化标准化的临床数据采集流程;(2)研究数据的采集分多个环节进行,每个环节由 1-2 名专人负责,严格遵 循研究方案和各项数据采集规范;(3)为研究人员提供关于技能操作、数据分析等培训课程并定期进行考核;(4)鼓励患者,家属及陪同人员积极主动参与随访,定期保持联系以减少失 访;(5)将失访率控制在10%以内,如有失访者或中途退出研究者,应记录分 析其原因并在以后的流程中积极改进;(6)数据的录入:双人复核数据确认后进行数据录入电脑系统,保证全流程 数据质量控制,确保数据的真实性和有效性。(7)成立监督小组,每 2周检查项目进度和实施情况。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

(1) Establish an organizational management system and develop standardized clinical data collection protocols; (2) Implement a multi-phase data collection process, with each phase overseen by 1-2 designated personnel who strictly adhere to the research protocol and data collection guidelines; (3) Provide researchers with training courses on technical operations and data analysis, with regular assessments conducted; (4) Encourage patients, family members, and accompanying personnel to actively participate in follow-up visits and maintain regular contact to minimize loss of follow-up; (5) Keep the loss of follow-up rate below 10%. Any cases of lost follow-ups or participants withdrawing from the study should be documented, analyzed, and improvements implemented in subsequent processes; (6) Data entry: After dual-person verification, data is entered into the computer system to ensure quality control throughout the process, guaranteeing data authenticity and validity.(7) A monitoring team will be established to review the project's progress and implementation every two weeks.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-04-13 15:01:57